Specifically, using a mouse model of NMYC-driven PTCL, they found that EZH2 acts as a cofactor of NMYC, activating expression of EZH2-NMYC bound sites without association with other canonical PRC2 components or activity (60). Here, MYCN is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.